Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

Minoru Fujimoto, Satoshi Serada, Masahiko Mihara, Yasushi Uchiyama, Hiroto Yoshida, Nobuo Koike, Yoshiyuki Ohsugi, Teppei Nishikawa, Barry Ripley, Akihiro Kimura, Tadamitsu Kishimoto, Tetsuji Naka

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Objective. To investigate the mechanism of interleukin-6 (IL-6) blockade in autoimmune arthritis, by comparing the effect of anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (mAb) treatment with the effect of soluble tumor necrosis factor (sTNFR)-Fc fusion protein treatment on T helper cell differentiation in collagen-induced arthritis (CIA). Methods. DBA/1 mice were immunized with type II collagen (CII) to induce arthritis and were left untreated or were treated with anti-IL-6R mAb or TNFR-Fc. T helper cell differentiation and cytokine expression during the development of arthritis in these mice were analyzed. Results. Immunization with CII predominantly increased the frequency of Th17 cells rather than Th1 cells. The frequency of FoxP3+ Treg cells was also increased after immunization. Treatment of mice with CIA with anti-IL-6R mAb on day 0 markedly suppressed the induction of Th17 cells and arthritis development, but treatment with this antibody on day 14 failed to suppress both Th17 differentiation and arthritis. In contrast, treatment of mice with CIA with TNFR-Fc from day 0 to day 14 suppressed neither Th17 differentiation nor arthritis, but treatment from day 21 to day 35 successfully ameliorated arthritis without inhibiting Th17 induction. Neither antibody treatment increased the frequency of Treg cells. Conclusion. Our results indicate that the protective effect of IL-6 blockade, but not tumor necrosis factor (TNF) blockade, in CIA correlates with the inhibition of Th17 differentiation. Our findings suggest that IL-6 blockade in rheumatoid arthritis in human is also likely to involve a therapeutic mechanism distinct from that of TNF blockade and thus may represent an alternative therapy for patients in whom the disease is refractory to TNF blockade.

Original languageEnglish
Pages (from-to)3710-3719
Number of pages10
JournalArthritis and Rheumatism
Volume58
Issue number12
DOIs
Publication statusPublished - 2008 Dec

Fingerprint

Arthritis
Interleukin-6
Experimental Arthritis
Interleukin-6 Receptors
Tumor Necrosis Factor-alpha
Th17 Cells
Monoclonal Antibodies
Regulatory T-Lymphocytes
Therapeutics
Cell Differentiation
Immunization
Inbred DBA Mouse
Th1 Cells
Collagen Type II
Antibodies
Complementary Therapies
Rheumatoid Arthritis
Cytokines
Proteins

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Fujimoto, M., Serada, S., Mihara, M., Uchiyama, Y., Yoshida, H., Koike, N., ... Naka, T. (2008). Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis and Rheumatism, 58(12), 3710-3719. https://doi.org/10.1002/art.24126

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. / Fujimoto, Minoru; Serada, Satoshi; Mihara, Masahiko; Uchiyama, Yasushi; Yoshida, Hiroto; Koike, Nobuo; Ohsugi, Yoshiyuki; Nishikawa, Teppei; Ripley, Barry; Kimura, Akihiro; Kishimoto, Tadamitsu; Naka, Tetsuji.

In: Arthritis and Rheumatism, Vol. 58, No. 12, 12.2008, p. 3710-3719.

Research output: Contribution to journalArticle

Fujimoto, M, Serada, S, Mihara, M, Uchiyama, Y, Yoshida, H, Koike, N, Ohsugi, Y, Nishikawa, T, Ripley, B, Kimura, A, Kishimoto, T & Naka, T 2008, 'Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses', Arthritis and Rheumatism, vol. 58, no. 12, pp. 3710-3719. https://doi.org/10.1002/art.24126
Fujimoto, Minoru ; Serada, Satoshi ; Mihara, Masahiko ; Uchiyama, Yasushi ; Yoshida, Hiroto ; Koike, Nobuo ; Ohsugi, Yoshiyuki ; Nishikawa, Teppei ; Ripley, Barry ; Kimura, Akihiro ; Kishimoto, Tadamitsu ; Naka, Tetsuji. / Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. In: Arthritis and Rheumatism. 2008 ; Vol. 58, No. 12. pp. 3710-3719.
@article{d7b68cd691ed4e4aab5ca1d639a4e176,
title = "Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses",
abstract = "Objective. To investigate the mechanism of interleukin-6 (IL-6) blockade in autoimmune arthritis, by comparing the effect of anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (mAb) treatment with the effect of soluble tumor necrosis factor (sTNFR)-Fc fusion protein treatment on T helper cell differentiation in collagen-induced arthritis (CIA). Methods. DBA/1 mice were immunized with type II collagen (CII) to induce arthritis and were left untreated or were treated with anti-IL-6R mAb or TNFR-Fc. T helper cell differentiation and cytokine expression during the development of arthritis in these mice were analyzed. Results. Immunization with CII predominantly increased the frequency of Th17 cells rather than Th1 cells. The frequency of FoxP3+ Treg cells was also increased after immunization. Treatment of mice with CIA with anti-IL-6R mAb on day 0 markedly suppressed the induction of Th17 cells and arthritis development, but treatment with this antibody on day 14 failed to suppress both Th17 differentiation and arthritis. In contrast, treatment of mice with CIA with TNFR-Fc from day 0 to day 14 suppressed neither Th17 differentiation nor arthritis, but treatment from day 21 to day 35 successfully ameliorated arthritis without inhibiting Th17 induction. Neither antibody treatment increased the frequency of Treg cells. Conclusion. Our results indicate that the protective effect of IL-6 blockade, but not tumor necrosis factor (TNF) blockade, in CIA correlates with the inhibition of Th17 differentiation. Our findings suggest that IL-6 blockade in rheumatoid arthritis in human is also likely to involve a therapeutic mechanism distinct from that of TNF blockade and thus may represent an alternative therapy for patients in whom the disease is refractory to TNF blockade.",
author = "Minoru Fujimoto and Satoshi Serada and Masahiko Mihara and Yasushi Uchiyama and Hiroto Yoshida and Nobuo Koike and Yoshiyuki Ohsugi and Teppei Nishikawa and Barry Ripley and Akihiro Kimura and Tadamitsu Kishimoto and Tetsuji Naka",
year = "2008",
month = "12",
doi = "10.1002/art.24126",
language = "English",
volume = "58",
pages = "3710--3719",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

AU - Fujimoto, Minoru

AU - Serada, Satoshi

AU - Mihara, Masahiko

AU - Uchiyama, Yasushi

AU - Yoshida, Hiroto

AU - Koike, Nobuo

AU - Ohsugi, Yoshiyuki

AU - Nishikawa, Teppei

AU - Ripley, Barry

AU - Kimura, Akihiro

AU - Kishimoto, Tadamitsu

AU - Naka, Tetsuji

PY - 2008/12

Y1 - 2008/12

N2 - Objective. To investigate the mechanism of interleukin-6 (IL-6) blockade in autoimmune arthritis, by comparing the effect of anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (mAb) treatment with the effect of soluble tumor necrosis factor (sTNFR)-Fc fusion protein treatment on T helper cell differentiation in collagen-induced arthritis (CIA). Methods. DBA/1 mice were immunized with type II collagen (CII) to induce arthritis and were left untreated or were treated with anti-IL-6R mAb or TNFR-Fc. T helper cell differentiation and cytokine expression during the development of arthritis in these mice were analyzed. Results. Immunization with CII predominantly increased the frequency of Th17 cells rather than Th1 cells. The frequency of FoxP3+ Treg cells was also increased after immunization. Treatment of mice with CIA with anti-IL-6R mAb on day 0 markedly suppressed the induction of Th17 cells and arthritis development, but treatment with this antibody on day 14 failed to suppress both Th17 differentiation and arthritis. In contrast, treatment of mice with CIA with TNFR-Fc from day 0 to day 14 suppressed neither Th17 differentiation nor arthritis, but treatment from day 21 to day 35 successfully ameliorated arthritis without inhibiting Th17 induction. Neither antibody treatment increased the frequency of Treg cells. Conclusion. Our results indicate that the protective effect of IL-6 blockade, but not tumor necrosis factor (TNF) blockade, in CIA correlates with the inhibition of Th17 differentiation. Our findings suggest that IL-6 blockade in rheumatoid arthritis in human is also likely to involve a therapeutic mechanism distinct from that of TNF blockade and thus may represent an alternative therapy for patients in whom the disease is refractory to TNF blockade.

AB - Objective. To investigate the mechanism of interleukin-6 (IL-6) blockade in autoimmune arthritis, by comparing the effect of anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (mAb) treatment with the effect of soluble tumor necrosis factor (sTNFR)-Fc fusion protein treatment on T helper cell differentiation in collagen-induced arthritis (CIA). Methods. DBA/1 mice were immunized with type II collagen (CII) to induce arthritis and were left untreated or were treated with anti-IL-6R mAb or TNFR-Fc. T helper cell differentiation and cytokine expression during the development of arthritis in these mice were analyzed. Results. Immunization with CII predominantly increased the frequency of Th17 cells rather than Th1 cells. The frequency of FoxP3+ Treg cells was also increased after immunization. Treatment of mice with CIA with anti-IL-6R mAb on day 0 markedly suppressed the induction of Th17 cells and arthritis development, but treatment with this antibody on day 14 failed to suppress both Th17 differentiation and arthritis. In contrast, treatment of mice with CIA with TNFR-Fc from day 0 to day 14 suppressed neither Th17 differentiation nor arthritis, but treatment from day 21 to day 35 successfully ameliorated arthritis without inhibiting Th17 induction. Neither antibody treatment increased the frequency of Treg cells. Conclusion. Our results indicate that the protective effect of IL-6 blockade, but not tumor necrosis factor (TNF) blockade, in CIA correlates with the inhibition of Th17 differentiation. Our findings suggest that IL-6 blockade in rheumatoid arthritis in human is also likely to involve a therapeutic mechanism distinct from that of TNF blockade and thus may represent an alternative therapy for patients in whom the disease is refractory to TNF blockade.

UR - http://www.scopus.com/inward/record.url?scp=57349083145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349083145&partnerID=8YFLogxK

U2 - 10.1002/art.24126

DO - 10.1002/art.24126

M3 - Article

VL - 58

SP - 3710

EP - 3719

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -